NCT05941507: A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 300 | Canada, US | LCB84, Anti-PD-1 monoclonal antibody | LigaChem Biosciences, Inc., AntibodyChem Biosciences, Inc. | Advanced Solid Tumors | 01/27 | 05/27 | | |
